MAAT PHARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.34 EUR | -1.27% |
|
-0.64% | +33.81% |
| May. 08 | Mickey Mouse on Wall Street |  |
| Apr. 15 | MaaT Pharma: positive data in graft-versus-host disease | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 4M 4.31M | Sales 2025 * | 4.4M 4.74M | Capitalization | 108M 117M |
|---|---|---|---|---|---|
| Net income 2024 * | -29M -31.23M | Net income 2025 * | -29M -31.23M | EV / Sales 2024 * | 32.7 x |
| Net Debt 2024 * | 22.5M 24.23M | Net Debt 2025 * | 53.7M 57.83M | EV / Sales 2025 * | 36.8 x |
| P/E ratio 2024 * |
-3.66
x | P/E ratio 2025 * |
-3.63
x | Employees | 56 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 55.48% |
More Fundamentals
* Assessed data
More news
Latest transcript on MaaT Pharma
More press releases
More news
| 1 day | -1.27% | ||
| 1 week | -0.64% | ||
| Current month | +0.43% | ||
| 1 month | -2.71% | ||
| 3 months | +33.43% | ||
| 6 months | +15.88% | ||
| Current year | +33.81% |
1 week
9.26
9.58
1 month
8.609.90
Current year
6.409.90
1 year
4.509.90
3 years
4.5014.40
5 years
4.5014.40
10 years
4.5014.40
| Managers | Title | Age | Since |
|---|---|---|---|
Hervé Affagard
FOU | Founder | - | 13-12-31 |
Siân Crouzet
DFI | Director of Finance/CFO | - | 15-12-31 |
| Chief Tech/Sci/R&D Officer | - | 22-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 13-12-31 | |
Claude Bertrand
BRD | Director/Board Member | 61 | 20-07-15 |
Muriel Prudent
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 9.34 | -1.27% | 319 |
| 24-05-09 | 9.46 | 0.00% | 282 |
| 24-05-08 | 9.46 | +0.64% | 284 |
| 24-05-07 | 9.4 | +1.08% | 1,140 |
| 24-05-06 | 9.3 | -1.06% | 629 |
Real-time Euronext Paris, May 10, 2024 at 11:05 am EDT
More quotes
MaaT Pharma is specialized in the research and development of microbiome biotherapies for use in the treatment of solid cancer tumors.
The company has a portfolio of 2 products in clinical development, including 1 in Phase III (MaaT013 for the treatment of acute graft-versus-host disease) and 1 in Phase IIb (MaaT033 for the prevention of complications of allogeneic hematopoietic stem cell transplantation), and 1 product in preclinical development (MaaT03X for the improvement of the response to immune checkpoint inhibitors in various types of solid tumors).
Calendar
2024-05-13
- Q1 2024 Sales and Revenue Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
9.34
EUR
Average target price
15.5
EUR
Spread / Average Target
+65.95%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +33.81% | 117M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- MAAT Stock